Cargando…

GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer

Anaplastic lymphoma kinase (ALK) fusion is found in ~3%–5% of patients with non-small-cell lung cancers (NSCLCs). Although the third-generation ALK tyrosine kinase inhibitor (TKI) lorlatinib shows high clinical efficacy in ALK-positive NSCLC, most of the patients eventually relapse with acquired res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shimizu, Yuki, Okada, Koutaroh, Adachi, Jun, Abe, Yuichi, Narumi, Ryohei, Uchibori, Ken, Yanagitani, Noriko, Koike, Sumie, Takagi, Satoshi, Nishio, Makoto, Fujita, Naoya, Katayama, Ryohei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931094/ https://www.ncbi.nlm.nih.gov/pubmed/35301419 http://dx.doi.org/10.1038/s41698-022-00260-0

Ejemplares similares

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
por: Mizuta, Hayato, et al.
Publicado: (2021)

Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK‐rearranged non–small cell lung cancer
por: Sakashita, Takuya, et al.
Publicado: (2022)

Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non‐small cell lung cancer
por: Takahashi, Ken, et al.
Publicado: (2020)

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance
por: Okada, Koutaroh, et al.
Publicado: (2019)

Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer
por: Katayama, Yuki, et al.
Publicado: (2023)

Drug resistance mechanisms in Japanese anaplastic lymphoma kinase‐positive non–small cell lung cancer and the clinical responses based on the resistant mechanisms
por: Yanagitani, Noriko, et al.
Publicado: (2020)

Pan‐HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK ‐rearranged lung cancer
por: Taniguchi, Hirokazu, et al.
Publicado: (2022)

Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity
por: Yoshizawa, Takahiro, et al.
Publicado: (2021)

Systematic identification of ALK substrates by integrated phosphoproteome and interactome analysis
por: Adachi, Jun, et al.
Publicado: (2022)

Monitoring epidermal growth factor receptor C797S mutation in Japanese non–small cell lung cancer patients with serial cell‐free DNA evaluation using digital droplet PCR
por: Ariyasu, Ryo, et al.
Publicado: (2021)

HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features
por: Tanimura, Keiko, et al.
Publicado: (2022)

Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib
por: Takeyasu, Yuki, et al.
Publicado: (2022)

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer
por: Katayama, Ryohei, et al.
Publicado: (2015)

A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan
por: Goto, Yasushi, et al.
Publicado: (2023)

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
por: Uchibori, Ken, et al.
Publicado: (2017)

Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis
por: Hochmair, Maximilian J., et al.
Publicado: (2020)

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
por: Katayama, Ryohei, et al.
Publicado: (2019)

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report
por: Thummalapalli, Rohit, et al.
Publicado: (2023)

Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation
por: Sagawa, Ray, et al.
Publicado: (2022)

First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN
por: Hayashi, Hidetoshi, et al.
Publicado: (2023)

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
por: Yun, Mi Ran, et al.
Publicado: (2019)

Efficacy of lorlatinib treatment in ALK rearrangement lung cancer with severe symptomatic central nervous system metastases and poor performance status
por: Taketa, Tomoyo, et al.
Publicado: (2021)

Clinical Responses to Crizotinib, Alectinib, and Lorlatinib in a Metastatic Colorectal Carcinoma Patient With ALK Gene Rearrangement: A Case Report
por: He, Xi, et al.
Publicado: (2021)

Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib
por: Gower, Arjan, et al.
Publicado: (2020)

TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity
por: Ogura, Hayato, et al.
Publicado: (2017)

Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET
por: Collier, T. Lee, et al.
Publicado: (2017)

Lorlatinib-Induced Pulmonary Embolism in a Patient With an ALK-Positive NSCLC
por: Toyozawa, Ryo, et al.
Publicado: (2020)

Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma
por: Suk, Yujin, et al.
Publicado: (2023)

Drug resistance in anaplastic lymphoma kinase‐rearranged lung cancer
por: Katayama, Ryohei
Publicado: (2018)

Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial
por: Shaw, Alice T., et al.
Publicado: (2017)

Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases
por: Zhu, Viola W, et al.
Publicado: (2020)

Response to lorlatinib on a patient with ALK‐rearranged non‐small cell lung cancer harboring 1151Tins mutation with uterine metastasis
por: Kobayashi, Takashi, et al.
Publicado: (2021)

Multiple Genetic Alterations as Resistance Mechanism during Second-Line Lorlatinib for Advanced ALK-Rearranged Lung Adenocarcinoma: A Case Report
por: Catino, Annamaria, et al.
Publicado: (2022)

Safety of lorlatinib following alectinib-induced pneumonitis in two patients with ALK-rearranged non-small cell lung cancer: a case series
por: Myall, Nathaniel J., et al.
Publicado: (2021)

Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC
por: Yun, Karen M, et al.
Publicado: (2022)

Successful treatment of refractory brain metastases from ALK‐positive lung cancer with lorlatinib
por: Nakagawa, Yoshiko, et al.
Publicado: (2022)

HGG-08. Lorlatinib for the treatment of ALK fusion positive infant high grade glioma
por: Greenwell, Alyssa, et al.
Publicado: (2022)

Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells
por: Verdura, Sara, et al.
Publicado: (2022)

Case report: ATIC-ALK fusion in infant-type hemispheric glioma and response to lorlatinib
por: Shahab, Shubin W., et al.
Publicado: (2023)

Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
por: Bauer, Todd M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5hc94fnd56qhd628cng4r515rb